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Osaka 565-0871, JapanBackground & Aims: Hepatocyte transplantation is one of the
most attractive approaches for the treatment of patients with
liver failure. Because human induced pluripotent stem cell-
derived hepatocyte-like cells (iPS-HLCs) can be produced on a
large scale and generated from a patient with liver failure, they
are expected to be used for hepatocyte transplantation. However,
when using conventional transplantation methods, i.e., intrasple-
nic or portal venous infusion, it is difficult to control the engraft-
ment efficiency and avoid unexpected engraftment in other
organs because the transplanted cells are delivered into blood cir-
culation before their liver engraftment.
Methods: In this study, to resolve these issues, we attempted to
employ a cell sheet engineering technology for experimental hep-
atocyte transplantation. The human iPS-HLC sheets were
attached onto the liver surfaces of mice with liver injury.
Results: This method reduced unexpected engraftment in organs
other than the liver compared to that by intrasplenic transplanta-
tion. Human albumin levels in the mice with human
iPS-HLC sheets were significantly higher than those in the
intrasplenically-transplanted mice, suggesting the high potential
for cell engraftment of the sheet transplantation procedure. In
addition, human iPS-HLC sheet transplantation successfully ame-
liorated lethal acute liver injury induced by the infusion of carbon
tetrachloride (CCl4). Moreover, we found that the hepatocyte
growth factor secreted from the human iPS-HLC sheet played
an important role in rescuing of mice from acute hepatic failure.Journal of Hepatology 20
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Hepatocyte transplantation is one of the most attractive
approaches for the treatment of patients with liver failure,
including patients with hepatocellular carcinoma, and drug-
induced liver injury. However, the use of human hepatocytes
presents difficulties due to the limited variety of donor sources,
limited cell proliferation potential, and allogenic immune rejection
in the transplantation setting. Because human induced pluripo-
tent stem cells (iPSCs) [1] can proliferate infinitely and can be
generated from a patient with liver failure, human iPSC-derived
hepatocyte-like cells (iPS-HLCs) have the potential to resolve
these problems, and are expected to be used in hepatocyte trans-
plantation. We have recently succeeded in generating highly
functional human iPS-HLCs by a combination of overexpression
of hepatic transcription factors and three-dimensional (3D) cul-
ture [2–5]. The hepatic gene expression levels of the human
iPS-HLCs were comparable to those of primary human hepato-
cytes [4]. Therefore, we anticipate that our human iPS-HLCs
may be a potential cell source for hepatocyte transplantation.
Experimental investigations using rodent models are expected
to contribute technical improvements to the clinical methods of
hepatocyte transplantation. In previous reports, human hepato-
cytes and human iPS-HLCs were transplanted into the rodents
with liver injury by either intrasplenic or portal venous infusion
[6–8]. These hepatocyte transplantation methods have some
disadvantages, including difficulties with the regulation of16 vol. 64 j 1068–1075
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engraftment efficiency and the potential for engraftment in other
organs, since the transplanted hepatocytes are distributed into
other organs as well as the liver following delivery through blood
circulation [9,10]. Although several groups have transplanted
human iPS-HLCs into mice [8,11,12], the engraftment efficiencies
in the transplanted mice were limited. Moreover, researchers
recently reported that the transplanted cells were engrafted at
an unexpected site; the peritoneum [8]. Therefore, the methods
of iPS-HLC transplantation must be improved before their clinical
use in human transplantation.
Recently, a cell sheet-based tissue engineering approach has
attracted much attention in cell transplantation therapy [13–
17] because of its potential for delivering a large number of cells
to the desired organ without loss of transplanted cells. A previous
study has shown that the cell viability after islet cell sheet trans-
plantation was higher than that after direct cell infusion [18].
Moreover, cell sheet transplantation of myoblasts and cardiac
cells provided higher therapeutic values and achieved greater
amelioration of heart failure in mice than a direct cell infusion
approach [19,20]. Therefore, it might be reasonable to expect that
a cell sheet engineering approach would realize improvements in
the control of engraftment efficiency and the avoidance of unex-
pected site engraftment of human iPS-HLCs. To date, several
researchers have conducted hepatocyte sheet transplantation
into ectopic sites (e.g., the subcutaneous space) and succeeded
in achieving therapeutic values in experimental animal models
[14–16]. However, the feasibility and therapeutic values of
human iPS-HLC sheet transplantation on the liver surface (ortho-
tropic transplantation) have yet to be clarified.
In the present study, we first created the human iPS-HLC
sheets by culturing the human iPS-HLCs in Temperature-
Responsive Culture Dishes (TRCDs) [21] and then harvesting
them in a sheet format using temperature change-dependent cell
harvesting. We then transplanted the human iPS-HLCs to
two-thirds partially hepatectomized mice either by a cell sheet
transplantation or direct cell infusion method (infused
intrasplenically). To compare the safety of these two transplanta-
tion methods, the distribution of the transplanted cells in these
recipient mice was assessed by semi-quantitative PCR. In
addition, the human albumin (ALB) levels in these recipient mice
serum were measured to assess the engraftment efficiency of the
human iPS-HLCs in these two transplantation methods. More-
over, we conducted an additional experiment to determine the
therapeutic value of human iPS-HLC-based cell transplantation.
To induce lethal acute liver failure, we administered carbon tetra-
chloride (CCl4) to the mice before transplantation of the human
iPS-HLC sheet or the human iPS-HLC suspension, and then we
assessed the survival rates in each groups.Materials and methods
Cell sheet-harvesting procedure
On day 35, human iPS-HLCs were seeded onto a 24-well TRCD (CellSeed). Two
days after the seeding, the human iPS-HLC sheet was harvested as a contiguous
cell sheet by using a CellShifter (CellSeed) support membrane according to the
manufacturer’s instructions with some modifications. CellShifter was developed
exclusively for harvesting cells as a cell sheet. Briefly, on day 37, a CellShifter sup-
port membrane was cut in half (approximately 0.95 cm2/piece), and one of the
half sheets was placed on top of the human iPS-HLCs. The culture temperature
was then decreased to 20 C for 30 min, and the CellShifter support was removed.
The human iPS-HLCs were thus harvested as a monolayer cell sheet attached to
the CellShifter support.Journal of Hepatology 2016Transplantation of the hepatocyte-like cells
Before transplantation, the liver capsules of intended sites were removed by rub-
bing the liver surface using a swab. To transplant the harvested human iPS-HLC
sheet, the sheet was placed onto the liver surface of recipient mice with the Cell-
Shifter. Approximately 5 min later, the CellShifter was removed while leaving the
human iPS-HLC sheet on the liver surface of the recipient mice. These operations
were repeated. The number of human iPS-HLCs transplanted in this manner was
approximately 8  105. In sham-operated mice, an unused CellShifter support
(i.e., without attached iPS-HLCs) was placed onto the liver surface and removed
approximately 5 min later, and this procedure was also repeated in the same
way as in the experimental group. To prepare the human iPS-HLC suspension,
the harvested human iPS-HLC sheet was suspended into the hepatocyte culture
medium (Lonza) using 0.05% trypsin (Invitrogen). A suspension of 8  105 viable
human iPS-HLCs was then infused into the inferior splenic pole of recipient mice.
Note that the total cell number transplanted per mouse was equal between the
human iPS-HLC sheet and human iPS-HLC suspension group. These procedures
were finalized by closing the skin wound.Results
To generate the human iPS-HLCs, hepatic differentiation was per-
formed using a combination of stage-specific transient transduc-
tion of FOXA2/HNF1a and monolayer/3D culturing as shown in
Fig. 1A [4]. To evaluate the hepatic characteristics of the human
iPS-HLCs, the gene expression levels of hepatocyte-related mark-
ers were examined (Fig. 1B–E). The results showed that the gene
expression levels of alpha-1-antitrypsin (aAT), cytochrome P450
3A4 (CYP3A4), and CYP1A2 in the human iPS-HLCs were compara-
ble to those in primary human hepatocytes that were cultured
48 h after plating the cells (PHH48hr) (Fig. 1B, D, and E, respec-
tively). The gene expression level of ALB in the human iPS-HLCs
was significantly higher than that of PHH48hr (Fig. 1C). More-
over, the percentages of both ALB- and asialoglycoprotein recep-
tor 1 (ASGR1)-positive cells were approximately 80% (Fig. 1F). In
contrast, the percentage of keratin 7 (CK7; a cholangiocyte
marker)-positive cells was approximately 20% (Supplementary
Fig. 1) Thus, these results suggested that the human iPS-HLCs
were efficiently and almost homogeneously generated from
human iPSCs in this study, just as in our previous study [4,22].
On day 35, the human iPS-HLCs were passaged and cultured on
a TRCD for 2 days, and then the human iPS-HLC sheets were har-
vested using a CellShifter by reducing the culture temperature to
20 C for 30 min. At that time, the vertical sections of the har-
vested human iPS-HLC sheet were prepared (Fig. 1G–I). We found
that the human iPS-HLCs were successfully harvested in a mono-
layer cell sheet format (Fig. 1G). Immunofluorescence staining
revealed that the human iPS-HLCs in a sheet format were positive
for hepatic markers (cytokeratin (CK) 18 and alpha-1-antitrypsin
(aAT)) (Fig. 1H and I, respectively). Therefore, we confirmed that
the human iPS-HLC sheets were successfully fabricated using a
TRCD and a CellShifter. Based on this information, we further
conducted transplantation experiments to determine the feasibil-
ity and the therapeutic values of cell transplantation using
the human iPS-HLC sheets. The transplantation procedure
is schematically shown in Fig. 1J. An image of the human
iPS-HLC sheets attached onto the mouse liver surface is shown
in Fig. 1K.
In order to determine the usefulness of the human iPS-HLC
sheets as a novel form of hepatocyte transplantation, the human
iPS-HLC sheets or human iPS-HLC suspension were transplanted
into the two-thirds partially hepatectomized mice (PHx mice).
First, the distribution of the transplanted cells was examined byvol. 64 j 1068–1075 1069
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Fig. 1. Experimental protocol for human iPS-HLC sheet transplantation onto the recipient mouse liver surface. (A) The procedure for differentiation of human iPS cells
(Dotcom) into HLC via mesendoderm cells, definitive endoderm cells, and hepatoblast-like cells. In the hepatic differentiation, not only the addition of growth factors but
also stage-specific transient transduction of both FOXA2- and HNF1a-expressing Ad vectors (Ad-FOXA2 and Ad-HNF1a, respectively) was performed. Further details of the
iPS-HLC differentiation procedure are described in the Supplementary materials and methods. The human iPS-HLCs were seeded on a temperature-responsive culture dish
(TRCD) on day 35. Two days after seeding, human iPS-HLC sheets were harvested as a contiguous cell sheet. (B–E) The gene expression levels of aAT (B), ALB (C), CYP3A4 (D),
and CYP1A2 (E) in human iPS-HLCs were measured by real-time RT-PCR. On the y axis, the gene expression levels in primary human hepatocytes (PHHs; three lots of PHHs
were used), which were cultured for 48 h after plating (PHH48hr), were taken as 1.0. (n = 3 each) (F) The efficiency of hepatocyte differentiation was measured by
estimating the percentage of ALB- (open) and ASGR1-positive cells (closed) using FACS analysis (n = 3 each). (G) Phase-contrast micrographs of the vertical sections of a
human iPS-HLC sheet. (H, I) Immunofluorescence staining of the hepatocyte markers (CK18: green (H); aAT: red (I)) in the human iPS-HLC sheet. Nuclei were
counterstained with DAPI (blue). (J) The human iPS-HLC sheet-harvesting steps and transplantation procedures. The human iPS-HLC sheets were harvested in a contiguous
cell sheet using a CellShifter support. The harvested human iPS-HLC sheet was placed onto the liver surface of the recipient mouse, and then the CellShifter was removed
while leaving the human iPS-HLC sheet on the liver surface of the recipient mice. These operations were repeated. (K) An image of the human iPS-HLC sheets transplanted
on the liver surface with the CellShifter. The scale bars represent 40 lm.
Research Articlesemi-quantitative PCR (Fig. 2). One day after transplantation, the
genomic DNA was extracted from various organs of the trans-
planted mice, and then the DNA fragments of human ALU and
mouse c-mos were amplified. In the human iPS-HLC sheet-
transplanted mice (sheet-mice), human DNA fragments were1070 Journal of Hepatology 2016detected only in the liver. By contrast, in the human iPS-HLC
intrasplenic transplanted mice (intrasplenic-mice), the human
DNA fragments were detected not only in the liver but also in
the spleen, stomach, and large intestine. Moreover, at 1 and
7 days after transplantation, immunohistochemical analysesvol. 64 j 1068–1075
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Fig. 2. Distribution of the transplanted human iPS-HLCs in mice. Human iPS
cells (Dotcom) were differentiated into the iPS-HLCs as described in Fig. 1A, and
then passaged onto a TRCD to generate the human iPS-HLC sheet. The human
iPS-HLC sheet or iPS-HLCs in suspension were transplanted into the two-thirds
partially hepatectomized mice (PHx mice). The distribution of transplanted
human iPS-HLCs in the recipient mice was examined by semi-quantitative PCR.
One day after transplantation, the liver, spleen, stomach, small intestine, large
intestine, brain, heart, lung, kidney, and pancreas were harvested and genomic
DNAs were extracted. The genomic DNAs of each group (human iPS-HLC sheet-
transplanted mice: sheet-mice; human iPS-HLC intrasplenic transplanted mice:
intrasplenic-mice; sham-operated mice: sham-mice; and human iPS-HLC (before
transplantation)) were pooled, respectively. Amplified DNA fragments of the
human ALU sequences are shown in the upper panel (h), and amplified DNA
fragments of the mouse c-mos are shown in the lower panel (m). The genome of
human iPS-HLC before transplantation was used as a control. (sheet-mice: n = 5;
others: n = 3).
JOURNAL OF HEPATOLOGYusing anti-HLA Class 1 ABC antibodies were performed to
examine the distribution of transplanted human iPS-HLCs in
the recipient mice (Supplementary Figs. 2, 3). Consistent with
the semi-quantitative PCR analysis, human cells (HLA Class 1
ABC-positive cells) were detected only in the liver of the sheet-
mice. We also confirmed that the 2-layered human tissue
expressing HLA Class 1 ABC was observed on the liver surface
of the sheet-mice at 1 day after transplantation (Supplementary
Fig. 2). On the other hand, human cells expressing HLA Class 1
ABC were found in the liver, spleen, and large intestine of the
intrasplenic-mice at both 1 and 7 days after transplantation.
These results suggest that the human iPS-HLC sheet transplanta-
tion could regulate the cell engraftment area while minimizing
the unregulated cell distribution to non-target sites.
Next, the engraftment efficiency of the human iPS-HLC sheet
and intrasplenic transplantation was examined. The human iPS-
HLCs were transduced with a luciferase-expressing Ad vector
before the transplantation, and then the amount of luciferaseJournal of Hepatology 2016activity detected from the recipient mouse livers was assessed
on the day after the transplantation (Fig. 3A). Luciferase expres-
sion was detectable in the livers of both sheet-mice and
intrasplenic-mice. The amount of luciferase activity detected in
the sheet-mice was significantly higher than that the
intrasplenic-mice. Additionally, we assessed human ALB serum
levels of the recipient mice at 2 weeks after the transplantation.
The human ALB serum levels in the sheet-mice (approximately
241 ± 40 ng/ml) was significantly higher than that in the
intrasplenic-mice (approximately 92 ± 33 ng/ml) (Fig. 3B). Taken
together, these data indicated that the engraftment efficiency of
human iPS-HLC sheet transplantation was significantly higher
than that of human iPS-HLC intrasplenic transplantation.
At 2 weeks after transplantation, we harvested the recipient
mouse livers for histological investigations, and observed a patch
of whitish tissues in the approximate shape of the transplanted
sheet on the liver surfaces (Fig. 3C). H&E staining was performed
on the sections of sheet-mice livers (Fig. 3D). This analysis
indicated that the engrafted sheets were successfully attached
on the liver surface of the host mice. To ascertain the human
liver-specific functionality of the engineered tissues, immunoflu-
orescence analyses were performed using anti-human-specific
antibodies for aAT and ALB. The engineered hepatic tissue on
the liver surface was found to be positive for both human aAT
and ALB (Fig. 3E–G). In addition, vascular-like structures made
up of the mouse CD31-expressing endothelial cells were
observed (Fig. 3H). To examine whether vascular-like structures
in these mice were functional, we injected fluorescent labeled
L. esculentum lectin, which has an ability to bind to vascular
endothelial cells [23]. The lectin bound to the luminal surface
of the vasculature in the engineered hepatic tissue (Fig. 3I), indi-
cating that the functional mouse blood vessel-like structures
might migrate into the graft. These results suggest that human
iPS-HLC sheet transplantation has the potential to enhance
engraftment efficiency as compared with the human iPS-HLC
intrasplenic transplantation. A long-term engraftment experi-
ment was performed (Supplementary Fig. 4A). The human ALB
serum levels in the sheet-mice reached a plateau at 4 weeks after
transplantation. Finally, at 8 weeks after transplantation, the
human ALB serum level in the sheet-mice was approximately
23.6 lg/ml. We confirmed that HLA Class 1 ABC-positive cells,
which were derived from the transplanted human cells, were
observed on the mouse liver surface even at 8 weeks after trans-
plantation (Supplementary Fig. 4B). These results suggest that the
engineered hepatic tissue stably engrafts on the liver surface.
To evaluate the therapeutic potential of the human iPS-HLC
sheet transplantation, the human iPS-HLC sheets or human
iPS-HLC in suspension were transplanted into the mice with
acute lethal liver injury induced by the inoculation of CCl4 at high
dose. The survival rate in the sheet-mice (63.2%) was significantly
higher than that in the intrasplenic-mice (33.3%) or sham-
operated mice (16.7%) (Fig. 4A). The intrasplenic transplantation
failed to achieve a significant improvement in survival rate over
the sham operation. One day after transplantation, although the
ALB serum levels of each group were similar (Fig. 4B), the AST
and ALT (liver damage markers) serum levels of sheet-mice were
lower than those of sham-mice (Fig. 4C and D, respectively). The
histological sections of the liver in sheet-mice group also demon-
strated that the number of apoptosis or coagulation necrosis of
mouse hepatocytes in sheet-mice was fewer than that in sham-
mice (Supplementary Fig. 5A, B). These data also suggest thatvol. 64 j 1068–1075 1071
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Research Articlethe human iPS-HLC sheet could decrease hepatic damage. Inter-
estingly, the hepatocyte growth factor (HGF) expression levels
in the human iPS-HLCs were comparable with those in human
bone marrow mesenchymal stromal cells (BM-MSCs) (Fig. 5A),1072 Journal of Hepatology 2016which exert hepatoprotective effects through secretion of HGF
[24,25]. Moreover, the engineered hepatic tissue on the liver sur-
face was also found to be positive for human HGF (Fig. 5B). It is
known that the HGF and c-met (HGF receptor) signaling pathwayvol. 64 j 1068–1075
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carbon tetrachloride (CCl4). At 36 h after transplantation, the livers of sheet-mice
were analyzed by immunohistochemical staining using anti-HLA Class 1 ABC and
anti-human HGF antibodies. The scale bars represent 40 lm. (C) The human
iPS-HLC sheet, which was transfected with si-control or si-HGF, was transplanted
into the mice that had been intraperitoneally inoculated with 3 ml/kg CCl4 1 day
before transplantation. The survival rate of the mice after transplantation with
the human iPS-HLC sheet transfected with si-control (si-control, circle; n = 14),
human iPS-HLC sheet transfected with si-HGF (si-HGF, triangle; n = 15), or sham
operation (sham-mice, square; n = 15) was examined. si-control vs. si-HGF:
p = 0.039; si-control vs. sham-mice: p = 0.002; si-HGF vs. sham-mice: p = 0.359.
JOURNAL OF HEPATOLOGYis required for liver regeneration and repair [26]. To investigate
whether HGF secreted from the transplanted human iPS-HLC
sheet could reduce hepatic damage, the human iPS-HLC sheet
transfected with a siRNA against HGF (si-HGF) was transplanted
into mice with acute lethal liver injury. The knockdown of HGF
expression in the human iPS-HLC sheet after transfection of
si-HGF was successfully confirmed (Supplementary Fig. 6A, B).
The survival rate of mice transplanted with si-HGF transfected
cells (20%) was significantly decreased when compared to that
of mice transplanted with si-control transfected cells (42.9%)
(Fig. 5C). Taken together, these results suggest that HGF secreted
from the human iPS-HLC sheet plays an important role in
prevention of mouse hepatocyte death through activation of the
HGF/c-met signaling pathway. Therefore, the human iPS-HLC
sheet transplantation would effectively contribute to hepatocyte
transplantation.Discussion
This study aimed to explore cell sheet-based and cell suspension-
based transplantation methods in order to improve the proce-
dures for human iPS-HLC-based therapy. As shown inJournal of Hepatology 2016Fig. 3A and B, we confirmed that our new human iPS-HLC sheet
transplantation method allowed considerable levels of cell
engraftment and liver-specific protein production in the
engrafted cells. In addition, the human iPS-HLC sheet transplan-
tation could efficiently rescue mice from CCl4-induced lethal
acute liver injury (Fig. 4A).vol. 64 j 1068–1075 1073
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These advantages of the sheet transplantation method were
attributed mainly to the difference in human iPS-HLC delivery
efficiency between the sheet and intrasplenic transplantation
methods. In the intrasplenic transplantation method, a large frac-
tion of transplanted cells (more than 70%) are rapidly removed by
phagocyte and macrophage responses [10,27]. This might be
because the transplanted hepatocytes lose contact with the
extracellular matrix or other cells in the initial period, in some
cases resulting in anoikis [28,29]. In contrast, anoikis of trans-
planted hepatocytes might be prevented in the sheet transplanta-
tion method [30] because the contacts between the cells and
extracellular matrix are preserved.
The level of luciferase production in the livers of sheet-mice
was approximately 24-fold higher than that in intrasplenic-
mice (Fig. 3A), although the serum human ALB levels of the
sheet-mice were only about 2.6-fold higher than those in the
intrasplenic-mice (Fig. 3B). This unexpectedly high human ALB
concentration in the serum of the intrasplenic-mice might be
explained by the finding that the intrasplenically injected human
iPS-HLCs did engraft various organs other than the liver, e.g., the
spleen, stomach, and large intestine (Fig. 2). Our findings are con-
sistent with previous studies, which have demonstrated that
some intrasplenically injected hepatocytes engraft into not only
the recipient liver but also the spleen, pancreas, and lung
[9,31]. Because it has been reported that hepatocytes engrafted
to the spleen have the ability to express ALB mRNA [31], the
serum human ALB levels in the intrasplenic-mice would be the
sum of human ALB produced by the engrafted human iPS-HLCs
in the liver and organs other than the liver.
We observed the stratified human iPS-HLCs on the liver sur-
face (Fig. 3E–G). More importantly, fine mouse vascular struc-
tures were formed in the stratified human iPS-HLC (Fig. 3H
and I). These results suggest that the newly developed mouse
blood vessels might supply the stratified human iPS-HLCs with
sufficient levels of nutrients and oxygen, and thereby protect
the stratified human iPS-HLCs from necrosis. In future experi-
ments, therefore, the potential for engineering thicker human
iPS-HLC tissues through the transplantation of multilayered
(i.e., more than three layers) human iPS-HLC sheets would be
worth exploring. In addition, number of cells that can be trans-
planted via the blood vessels is strictly limited due to blood
vessel embolism (approximately 1  106 cells/mouse) [32],
while a large number of cell can be transplanted using the cell
sheet transplantation method. Recently, Kawamura et al. [13]
succeeded in stratifying 7 layers of human iPS-derived car-
diomyocytes to create tissue on a porcine cardiac surface. If
successfully stratified, further higher therapeutic values could
be expected.
We found that the HGF secreted from the transplanted human
iPS-HLC sheet, could protect hepatocytes against cell death
(Fig. 5). Jin et al. have reported that HGF administration enhanced
the therapeutic effects of transplanted BMMCs in acute hepatic
injured mice [33]. Moreover, Asano et al. showed that HGF also
has the ability to promote remodeling in mouse liver fibrosis
[34]. Taken together, these results demonstrate that HGF has
great potential as an anti-apoptosis, anti-inflammation, and
anti-fibrosis agent [35,36]. However, the half-life of HGF is very
short (about 3.8 min) [37]. Therefore, continuous HGF secretion
is required to achieve the therapeutic effects. Thus, the human
iPS-HLC sheet transplantation could rescue hepatocytes from cell
death by activating HGF/c-Met signaling, because the human1074 Journal of Hepatology 2016iPS-HLC sheet stably engrafts on the liver surface and also stably
secretes HGF (Supplementary Figs. 4, 5B).
In this study, we established a feasible human iPS-HLC trans-
plantation technology. From the perspective of enhancing
engraftment efficiency and achieving regulated cell engraftment
sites, the present cell sheet-based transplantation method is
superior to conventional cell transplantation through blood cir-
culation. The transplantation method shown in this study would
be a powerful tool for cell transplantation and therapeutic tissue
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